GL 0817

Drug Profile

GL 0817

Alternative Names: GL-0817; MAGE-A3 vaccine

Latest Information Update: 24 Aug 2016

Price : $50

At a glance

  • Originator Mayo Clinic; University of Maryland, Baltimore
  • Developer Gliknik; University of Pennsylvania
  • Class Cancer vaccines; Peptides
  • Mechanism of Action Immunomodulators; MAGEA-3-protein-modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Head and neck cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Head and neck cancer
  • Clinical Phase Unknown Squamous cell cancer
  • No development reported Multiple myeloma

Most Recent Events

  • 16 Aug 2016 Gliknik plans a phase II trial for Squamous cell cancer (Adjuvant therapy, Second-line therapy or greater, Combination therapy) in USA, Czech Republic, Germany, Hungary, Poland, Spain, Serbia and Ukraine (IV) (NCT02873819)
  • 08 Aug 2016 Clinical trials in Squamous cell cancer in USA (IV) before August 2016
  • 14 Sep 2015 No recent reports of development identified - Phase-II for Multiple myeloma (Combination therapy, Late-stage disease) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top